Bone Cancer

1st Edition

Progression and Therapeutic Approaches

Editors: Dominique Heymann Dominique Heymann
Hardcover ISBN: 9780123748959
eBook ISBN: 9780080953885
Imprint: Academic Press
Published Date: 8th September 2009
Page Count: 504
95.00 + applicable tax
149.95 + applicable tax
145.00 + applicable tax
118.00 + applicable tax
Unavailable
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access


Description

The epidemiological and clinical importance of bone metastasis has long been recognized, but the past decade has seen an explosion in the fields of bone biology and bone cancer research. This period of time has been marked by a number of key discoveries that have led to the opening up of entirely new areas for investigation as well as new therapies which combine surgery and biological therapeutic approaches.

Bone is a common site of cancer metastases - cancer cells commonly develop in bone and spread to other organ systems through the bloodstream. For example, the incidence of bone metastases in breast and prostate cancers is 70%, whereas it is only 30 to 40% in metastatic lung cancer. In clinical terms, bone metastases have substantial negative effects on a patient's quality of life and are a main cause of patient mortality.

Given the global prevalence of breast and prostate cancers, knowledge of bone biology has become essential for the medical and cancer research communities. This book provides, all in one resource, the most recent data on bone cancer development (cellular and molecular mechanisms), genomic and proteomic analyses, clinical analyses (histopathology, imaging, pain monitoring), as well as new therapeutic approaches and clinical trials for primary bone tumors and bone metastases.

Key Features

    Feature

  • Presents a comprehensive, translational source for all aspects of bone cancer in one reference work
  • Bone cancer experts (from all areas of research and practice) take readers from the bench research (cellular and molecular mechanism), through genomic and proteomic analysis, all the way to clinical analysis (histopathology and imaging) and new therapeutic approaches.
  • Clear presentation by bone biologists of the cellular and molecular mechanisms underlying bone tumors and bone cancer metastasis as well as the genomic and proteomic assays used in detecting cancer within given organ systems
  • Clear presentation by oncologists and radiologists of how histopathology, imaging, and pain monitoring can lead to new therapeutic approaches
  • Benefit

  • Saves researchers and clinicians time in quickly accessing the very latest details on a broad range of bone cancer issues, as opposed to searching through thousands of journal articles.

  • Provides a common language for cancer researchers, bone biologists, oncologists, and radiologists to discuss bone tumors and how bone cancer metastases affects each major organ system
  • Correct diagnosis (and therefore correct treatment) of cancer depends on a strong understanding of the molecular basis for the disease – both oncologists and radiologists will benefit
  • Bone biologists will gain insight into how clinical observations and practices can feed back into the research cycle and will, therefore, be able to develop more targeted genomic and proteomic assays

Readership

Bone biologists, cancer researchers, oncologists, orthopedic surgeons, radiologists and other specialists in cancer imaging; Medical libraries; graduate academic libraries.

Table of Contents

Section 1: Genetic Control, Frequencies and Epidemiology of Bone Caner

1. Epidemiology of Primary Bone Tumors and Economical Aspects of Bone Metastases

Esther I. Hauben and Pancras C.W. Hogendoorn

Section 2: Bone Microenvironment and Bone Cancer

2. Tumor-Bone Cell Interactions in Bone Metastases

Pierrick G.J. Fournier, Lauren K. Dunn, Gregory A. Clines, Theresa A. Guise

3. Early Bone Metastasis-Associated Molecular and Cellular Events

Philippe Clezardin

4. Regulation of Osteoblast Differentiation and Bone Cancers by Wnt and Parathyroid Hormone Signaling Pathways

Julia Billiard, John A. Robinson, Ramesh A. Bhat, Bheem M. Bhat, Richard Murrills and Peter V.N. Bodine

5. Osteoclast Differentiation and Function

Luis Filgueira

6. Immunoregulation of Osteoclast Differentiation in Multiple Myeloma Bone Diseases

Maria Grano, Giacomina Brunetti and Silvia Colucci

7. Facts and Hypothesis on Osteolytic Lesions Related to Normal and Tumoral Epithelial Dental Cell Differentiation

Blandine Ruhin, Frederic Lezot, Aymann Bouattour, Sonia Ghoul-Mazghar, Ariane Berdal, Vianney Descroix

8. The Role of the Interleukin-6 Family of Cytokines in Bone Remodeling and Bone Cancer

Frederic Blanchard, Emmanuelle David, Bénédicte Brounais

9. Proteases and Therapeutic Approaches of Bone Tumors

Velasco C. Ruiz, Y. Fortun, Dominique Heymann, Marc Padrines

Section 3: and Bone Markers of Cancer (genes and proteins)

10.Bone Remodelling Markers and Bone Cancer

Markus J. Seibel

11. Cytogenetic and Molecular Genetic Alterations in Bone Tumors

Suvi Savola, Tom Böhling, Sakari Knuutila

12. Cytogenetic of Bone Tumors

Jiyun Lee, Mallory Martin

Details

No. of pages:
504
Language:
English
Copyright:
© Academic Press 2010
Published:
Imprint:
Academic Press
eBook ISBN:
9780080953885
Hardcover ISBN:
9780123748959

About the Editor

Dominique Heymann

Dominique Heymann studied cell biology, biochemistry and immunology in INSERM (French NIH) unit 211 at the University of Nantes and received his Ph.D. in 1995. He was appointed Associate Professor in 2001 in the Department of Histology and Embryology. In 2009, he was awarded a personal Chair of Histology and Embryology. Currently he is the Quality Control Manager of the Tissue Bank and Gene and Cellular Therapy Unit at Nantes Hospital. He heads a laboratory research group (INSERM UMR 957) of 65 people at the Faculty of Medicine, where the pathogenesis of primary bone tumours, and more specifically, the role of bone microenvironment (osteoclasts, mesenchymal stem cells, OPG/RANK/RANKL, IL-6 and MCSF cytokine family) in tumour growth is studied. In 2006, Dominique Heymann won the Paul Mathieu prize from the National Academy of Medicine for his work entitled “From the osteolytic process associated to primary bone tumors to the development of bi-therapies for osteosarcoma”. He was on the national scientific advisory board of INSERM (2008-2012) and is now Co-Chairman of INSERM scientific commission n°5 (“Physiology and pathophysiology of endocrine, bone, skin and gastrointestinal tissues”). He has authored approximately 180 publications in peer- reviewed journals, more than 300 abstracts and 20 book chapters. He is also Associate Editor of Life Sciences, Academic Editor of PLoS ONE, Editor-in-Chief of the Open Bone Journal and serves on the Editorial Board of Current Medicine Chemistry, European Journal of Pharmacology, and Journal of Bone Oncology.

Affiliations and Expertise

Professor, Faculty of Medicine, University of Nantes; Head of Pathophysiology of Bone Resorption and Therapy of Primitive Bone Tumors, INSERM, Nantes, France

Dominique Heymann

Dominique Heymann studied cell biology, biochemistry and immunology in INSERM (French NIH) unit 211 at the University of Nantes and received his Ph.D. in 1995. He was appointed Associate Professor in 2001 in the Department of Histology and Embryology. In 2009, he was awarded a personal Chair of Histology and Embryology. Currently he is the Quality Control Manager of the Tissue Bank and Gene and Cellular Therapy Unit at Nantes Hospital. He heads a laboratory research group (INSERM UMR 957) of 65 people at the Faculty of Medicine, where the pathogenesis of primary bone tumours, and more specifically, the role of bone microenvironment (osteoclasts, mesenchymal stem cells, OPG/RANK/RANKL, IL-6 and MCSF cytokine family) in tumour growth is studied. In 2006, Dominique Heymann won the Paul Mathieu prize from the National Academy of Medicine for his work entitled “From the osteolytic process associated to primary bone tumors to the development of bi-therapies for osteosarcoma”. He was on the national scientific advisory board of INSERM (2008-2012) and is now Co-Chairman of INSERM scientific commission n°5 (“Physiology and pathophysiology of endocrine, bone, skin and gastrointestinal tissues”). He has authored approximately 180 publications in peer- reviewed journals, more than 300 abstracts and 20 book chapters. He is also Associate Editor of Life Sciences, Academic Editor of PLoS ONE, Editor-in-Chief of the Open Bone Journal and serves on the Editorial Board of Current Medicine Chemistry, European Journal of Pharmacology, and Journal of Bone Oncology.

Affiliations and Expertise

Professor, Faculty of Medicine, University of Nantes; Head of Pathophysiology of Bone Resorption and Therapy of Primitive Bone Tumors, INSERM, Nantes, France

Reviews

"...Presents a comprehensive, translational source for all aspects of bone cancer in one reference work…Clear presentation...of how histopathology, imaging, and pain monitoring can lead to new therapeutic approaches."--Anticancer Research, February 2015

"Reviewing the current advances in the progression and therapeutic approaches to bone cancer is an extremely challenging task. Bone cancer is not a single disease; rather, it is a field comprising a diverse and complex range of malignancies, from primary bone tumors of stromal cell origin, to hematopoietic malignancies and secondary metastatic bone disease. Dominique Heymann has assembled an exciting, comprehensive and up-to-date series of reviews contributed by experts in the basic and clinical aspects of bone research. In the past decade, our understanding of cancers involving bone has increased tremendously, underpinned by advances in the cellular, molecular and biochemical mechanisms of bone cell interactions in health and disease, together with advances in genetics, diagnostics, imaging and therapeutic strategies. All these aspects are covered in this timely volume, which will galvanize further cooperative efforts in the coming years between basic researchers, oncologists and pathologists towards understanding the causes of different bone cancers and translating this knowledge into the clinic."

-- Agi E. Grigoriadis, PhD, Departments of Craniofacial Development and Orthodontics, King's College London, United Kingdom

"Our understanding of bone biology and diseases has strikingly progressed in the last decade. In parallel, the processes that lead to various forms of cancer have been further unraveled and the mechanisms leading to metastatic spread further explored. In this book, Dr. Heymann has gathered some of the world experts on these subjects to explore the cutting edge where these fields merge in the context of bone cancer